Valuation of Biosimilar and Key Value Drivers Dr. Patrik Frei October 2015 Biosimilars Asia

Size: px
Start display at page:

Download "Valuation of Biosimilar and Key Value Drivers Dr. Patrik Frei October 2015 Biosimilars Asia"

Transcription

1 Valuation of Biosimilar and Key Value Drivers Dr. Patrik Frei October 0 Biosimilars Asia

2 Agenda Introduction Valuation of Biosimilar Key Value Driver / Conclusion

3 Venture Valuation Independent assessment and valuation of Life Sciences companies / therapeutic products Company, Deals & Investors Database - Biotechgate.com - Switzerland (HQ); Canada; UK; Singapore; India; China - Global experience with people - Track record of over 0 valued companies / products - Investor clients such as Novartis, GSK, Fraunhofer Gesellschaft, European Investment Bank; Company clients: Arpida/Evolva; SC; - Product valuation for licensing deals

4 Valuation of Biosimilar Company Country Ownership Raised* m USD Cap. USD S Bio (SBio) Inc. China Public (IPO 0) 9.8Bn Coherus Biosciences, Inc. USA Public (IPO 0).0Bn BeiGene (Beijing) Co., Ltd China Private 7 XBiotech Inc. USA Public (IPO 0) 76.6M Momenta Pharmaceuticals USA Public (IPO 00) 7.Bn Oncobiologics, Inc. USA Private FINOX Biotech SwitzerlandPrivate * Raised in last years Source: Biotechgate.com

5 rnpv Product Valuation. Development phase => investment (r) => success rate. phase => revenues Patent expiry => end of revenues (often no terminal value). Discount / WACC => non-specific risk Cash Flow Time Development Phase

6 Five Step Process Determine Cash Flows in Development Phase Determine Cash Flows in Phase Discount with Adjust for Sum discounted cash flows 6

7 rnpv Example - Phase I product - % discount rate - % Probability of success (p to market) CF: USD 8m DCF: USD 6m rnpv: USD 0m 00'000 0'000 00'000 0'000 00'000 0'000 00'000 0' '000 Cash Flow Discounted CF rnpv '000 '000 0'000 '000 0'000 '000 0'000 ' '000-0'000 Discounted CF rnpv

8 Agenda Introduction Valuation of Biosimilar Key Value Driver / Conclusion 8

9 Development Phase Innovative Biologics Determine cost and duration of clinical trials Manufacturing Regulatory affairs Long term animal tox. studies Biosimilar Shorter development timelines / costs Finding patients for clinical trials Comparative trials => cost for original product 9

10 Cost and Lead Times Source: Bernstein Research USD -+bn USD 60 00m Source: Hospira 0

11 Reduce time to market Original product Biosimilar Phase I month / m month / m Phase II 6 month / 0m n/a Phase III 6 month / 0m 6 month / 60m Approval month / 8m month / 6m Total 8 years / m years / 68m rnpv USD 0m USD 0m

12 Phase Develop assumptions to predict the future market Methods used: Bottom-up approach - Based on primary market data Top-down approach - based on comparable products

13 Phase Biosimilar: - Different adaption of Biosimilar (EU / US; Germany vs. rest of Europe) - Uncertainty in future (reimbursement, incentives) - Average price cut of 0% - More patients? (price elasticity) - Different penetration (commodity vs. differentiation) - Competition (original product / biosimilar / biobetter) => share? Cash Flow Development Phase Time Original Biosimilar

14 Phase share: Global SalesAvastin0 7'00 Reduction in pricing 0% '80 Increase in reach due to lower prices % '97 Target indication(colorectalcancer, NSCLC) 80% '70 Competion new therapies 7% ' Competition Originatormarketshare % = '90 First to market Amgen % = 7 Phase III () probabilityadjusted 9% = Phase I () probabilityadjusted 7% = Pre-clinical() probability adjusted % = 76 Product to be valued (phase I) % = 6 Total 00% '

15 Reduced market Original product Biosimilar Peak sales (0) Life Cycle USD 98m Drop of sales after patent expiry USD 6m Growth of % per year rnpv USD 0 m USD -m

16 Cost of Equity / discount rate in rnpv: Early stage % - 8% Mid stage 0% - % Late stage 9% - 0% Pharma below 0% (incl. debt) Source. Cost of equity and non-development associated risks. 6

17 Used discount rate in rnpv: Biosimilar player => lower WACC; Generally higher uncertainty (+) % => USD 0m 8% => USD m % => USD m 7

18 Adjust for risk (I) Source: Nature Biotechnology; Clinical development success rates for investigational drugs; January 0 8

19 Adjust for (III) The relation between and Value Completion of a phase Direct value increase Original Biosimilar Cumulative Sucess rate: % Value 86% 6% % % Phase I Phase II Phase III NDA/BLA Approval/ 9

20 Adjust for risk (I) Used risk adjustment in rnpv: Biosimilar => lower risk (-) No phase II Individual adjustment Original product Biosimilar Phase I 6% 6% Phase IIa/IIb 60% / % 00% Phase III 6% 6% Approval 86% 86% Cum. Success % % rnpv USD 0m USD 9m 0

21 Summary Original product Biosimilar Costs m 68m Time to market 8 years years Sales 0 USD 98m USD 6m Cum. Success % % rnpv USD 0m USD m rnpv after phase III USD 69m USD 79m

22 Agenda Introduction Valuation of Biosimilar Key Value Driver / Conclusion

23 Key Value Driver Strategic decision to maximize value Value drivers are same as innovative drugs Variation on Timeline (+) Development costs (+) (-) Competition Pricing Accessible market Attrition rate (+) (+/-) => / Competition / Pricing as high impact

24 Thank you for listening! Slides available on => resource center Tel.: Venture Valuation Switzerland / Singapore p.frei@venturevaluation.com

Valuation and HealthTech in Asia Dr. Patrik Frei January 2017 San Francisco

Valuation and HealthTech in Asia Dr. Patrik Frei January 2017 San Francisco Valuation and HealthTech in Asia Dr. Patrik Frei January 2017 San Francisco Overview Introduction to Valuation Valuation of a Company / Therapeutic Product Valuation in Asia / HealthTech Asia's healthcare

More information

Swiss Medtech - Europe Medtech Development Dr. Patrik Frei September 2014 Suzhou

Swiss Medtech - Europe Medtech Development Dr. Patrik Frei September 2014 Suzhou Swiss Medtech - Europe Medtech Development Dr. Patrik Frei September 2014 Suzhou 1 Overview 1. Overview European Medtech Venture Valuation: Independent assessment and valuation of technology driven companies

More information

Global Oncology Biosimilars Market

Global Oncology Biosimilars Market Published on Market Research Reports Inc. (https://www.marketresearchreports.com) Home > Global Oncology Biosimilars Market 2016-2020 Global Oncology Biosimilars Market 2016-2020 Publication ID: TNV0216071

More information

Building Biotech Technology Transfer Opportunities: Sponsor and Developer Strategies for Success

Building Biotech Technology Transfer Opportunities: Sponsor and Developer Strategies for Success Building Biotech Technology Transfer Opportunities: Sponsor and Developer Strategies for Success Drug developers have long been under pressure to introduce new products in an environment of escalating

More information

Valuing and Licensing Intellectual Property. Richard Williams

Valuing and Licensing Intellectual Property. Richard Williams c Healthcare Valuing and Licensing Intellectual Property Richard Williams 9 May 2001 Agenda Exploitation of intellectual property The licence route- why and when? Choosing a partner Practical considerations

More information

Swiss Biotechnology Venture Capital

Swiss Biotechnology Venture Capital TINSSA Swiss Biotechnology Venture Capital Patrik Frei Johannesburg, October 2005 Agenda Venture Valuation Valuation Swiss Biotechnology Venture Capital in Switzerland Venture Valuation Valuation Services

More information

Building Biotech Technology Transfer Opportunities

Building Biotech Technology Transfer Opportunities HEALTHCARE Building Biotech Technology Transfer Opportunities Sponsor and developer strategies for success By Alison Sahoo Alison Sahoo Alison Sahoo is a pharmaceutical industry analyst with more than

More information

Guide to Valuation of Pharmaceutical Licensing Deals Table of Contents

Guide to Valuation of Pharmaceutical Licensing Deals Table of Contents Guide to Valuation of Pharmaceutical Licensing Deals 2015 Table of Contents IMS HEALTH 210 Pentonville Road London N1 9JY United Kingdom Tel: +44 (0)20 3075 5876 For enquiries, please contact: Denis Mason

More information

Sirtex Medical Limited

Sirtex Medical Limited Sirtex Medical Limited Market Update 2011 Half Year Results Gilman Wong CEO Darren Smith CFO 9-10 March 2011 SIR-Spheres is a registered trademark of Sirtex SIR-Spheres Pty Ltd. Understanding the Sirtex

More information

DEMONSTRATING YOUR MEDICINE S VALUE TO ALL STAKEHOLDERS TRUSTED COMMERCIALIZATION AND MARKET ACCESS EXPERTISE

DEMONSTRATING YOUR MEDICINE S VALUE TO ALL STAKEHOLDERS TRUSTED COMMERCIALIZATION AND MARKET ACCESS EXPERTISE CATALYSTS DRIVING SUCCESSFUL DECISIONS IN LIFE SCIENCES DEMONSTRATING YOUR MEDICINE S VALUE TO ALL STAKEHOLDERS TRUSTED COMMERCIALIZATION AND MARKET ACCESS EXPERTISE WHEN COMMERCIALIZING A MEDICINE, IT

More information

B : Topics in Investments - Financial Analysis in Healthcare

B : Topics in Investments - Financial Analysis in Healthcare B40.3176: Topics in Investments - Financial Analysis in Healthcare Professor: Roderick Wong, MD Phone: 917-453-3849 Office: KMC 9-150 Email: rodwong@gmail.com Hours: By appointment COURSE BACKGROUND The

More information

M&A Focus: Biotechnology

M&A Focus: Biotechnology WWW.IBISWORLD.COM Month 2012 1 Follow on head on Master page A May 2013 M&A Focus: Biotechnology By Anna Son Growing pains from the Patent Cliff will lead Big Pharma companies to invest in promising biotechnology,

More information

Challenges and Opportunities in Pharma: Perspective for an Emerging Middle East April 24th, 2015

Challenges and Opportunities in Pharma: Perspective for an Emerging Middle East April 24th, 2015 Challenges and Opportunities in Pharma: Perspective for an Emerging Middle East 2020 April 24th, 2015 Content Pharma Market Landscape Global Pharma Market Market Categories Middle East Markets Major Challenges

More information

An exploration of the Contract Research Organisation sector in. Divya Bhagianadh

An exploration of the Contract Research Organisation sector in. Divya Bhagianadh An exploration of the Contract Research Organisation sector in India Divya Bhagianadh Global scenario Outsourcing clinical trials- the new trend Estimated CRO market revenues 2000-2010e ($ bn) Total market

More information

Santen Acquisition of InnFocus, Developer of MicroShunt Glaucoma Implant Device

Santen Acquisition of InnFocus, Developer of MicroShunt Glaucoma Implant Device Santen Acquisition of InnFocus, Developer of MicroShunt Glaucoma Implant Device Akira Kurokawa President & CEO August 2, 2016 Copyright 2016 Santen Pharmaceutical Co., Ltd. All rights reserved. 1 External

More information

PAUL CLAYDON. Partner and European Head of Pharmaceuticals and Biotechnology Group. May 2001

PAUL CLAYDON. Partner and European Head of Pharmaceuticals and Biotechnology Group. May 2001 PAUL CLAYDON Partner and European Head of Pharmaceuticals and Biotechnology Group May 2001 1 M&A: INDUSTRY TRENDS IN THE LIFE SCIENCES European Biotech Sector European companies using modern biological

More information

INVESTOR PRESENTATION FULL YEAR 2007 RESULTS. February 2008

INVESTOR PRESENTATION FULL YEAR 2007 RESULTS. February 2008 INVESTOR PRESENTATION FULL YEAR 2007 RESULTS February 2008 FORWARD LOOKING STATEMENTS This presentation contains forward looking statements. The words believe, expect, anticipate, intend, will, may, would,

More information

INVESTOR PRESENTATION

INVESTOR PRESENTATION INVESTOR PRESENTATION March 2008 FORWARD LOOKING STATEMENTS This presentation contains forward looking statements. The words believe, expect, anticipate, intend, will, may, would, could and plan and similar

More information

MAKING MARKETS FOR VACCINES A HISTORIC CALL FOR ACTION. May 7, 2005

MAKING MARKETS FOR VACCINES A HISTORIC CALL FOR ACTION. May 7, 2005 MAKING MARKETS FOR VACCINES A HISTORIC CALL FOR ACTION May 7, 2005 BIO Ventures for Global Health 1225 Eye Street, NW, Suite 400 Washington, DC 20005 202-962-9216 www.bvgh.org Making Markets for Vaccines

More information

CTS East Coast. Increasing Agility and Innovation in the Clinical Supply Chain for Cost Optimization. Connect with us to connect with Asia

CTS East Coast. Increasing Agility and Innovation in the Clinical Supply Chain for Cost Optimization. Connect with us to connect with Asia Increasing Agility and Innovation in the Clinical Supply Chain for Cost Optimization Connect with us to connect with Asia CTS East Coast Oct 19 th, 2011 Philadelphia Introduction Zuellig Pharma Asia Pacific

More information

Pharmaceutical Product Development NASDAQ: PPDI. Dan Darazsdi Chief Financial Officer. Credit Suisse Healthcare Conference November 2009

Pharmaceutical Product Development NASDAQ: PPDI. Dan Darazsdi Chief Financial Officer. Credit Suisse Healthcare Conference November 2009 Pharmaceutical Product Development NASDAQ: PPDI Dan Darazsdi Chief Financial Officer Credit Suisse Healthcare Conference 2009 12 November 2009 Safe Harbor Except for historical information, all of the

More information

ESTIMATE THE IMPACT OF TIME SAVINGS ON YOUR DRUG DEVELOPMENT PROGRAM, ASSET VALUE AND FINANCIAL COMPANY PERFORMANCE

ESTIMATE THE IMPACT OF TIME SAVINGS ON YOUR DRUG DEVELOPMENT PROGRAM, ASSET VALUE AND FINANCIAL COMPANY PERFORMANCE ESTIMATE THE IMPACT OF TIME SAVINGS ON YOUR DRUG DEVELOPMENT PROGRAM, ASSET VALUE AND FINANCIAL COMPANY PERFORMANCE An Economic Comparison of Programmatic and Transactional Development Models PETER SAUSEN,

More information

Australian Healthcare Sector - Performance and Investors Taste

Australian Healthcare Sector - Performance and Investors Taste 5 th September 2012 INDUSTRY REPORT INDUSTRY REPORT Australian Healthcare Sector - Performance and Investors Taste What s New? Why Read This? Anton Uvarov PhD Senior Analyst Guy Le Page Head of Research

More information

Inaugural Fraunhofer Delaware Technology Summit

Inaugural Fraunhofer Delaware Technology Summit Inaugural Fraunhofer Delaware Technology Summit Energy and Life Sciences Solu

More information

REFERENCE CODE GDHC1180DFR PUBLICATION DATE M AY 2013

REFERENCE CODE GDHC1180DFR PUBLICATION DATE M AY 2013 REFERENCE CODE GDHC1180DFR PUBLICATION DATE M AY 2013 STELARA (PSORIASIS) - Executive Summary Table below presents key metrics for Stelara in the seven of the nine major pharmaceutical markets. Stelara:

More information

Antisense Therapeutics Ltd ASX:ANP January 2017

Antisense Therapeutics Ltd ASX:ANP January 2017 Antisense Therapeutics Ltd ASX:ANP January 2017 Forward Looking Statements This presentation contains forward-looking statements regarding the Company s business and the therapeutic and commercial potential

More information

PREVIEW. Benchmarking European Investigator Payments Industry Standard Research

PREVIEW. Benchmarking European Investigator Payments Industry Standard Research PREVIEW Benchmarking European Investigator Payments Info@ISRreports.com 2014 Industry Standard Research www.isrreports.com Report Overview This report provides an analysis of Europe s clinical trial compensation

More information

Bio-Pharma: China A Look at The FUTURE: 4 th & 5 th Generation Global Strategies

Bio-Pharma: China A Look at The FUTURE: 4 th & 5 th Generation Global Strategies Global Strategy Global Challenges Executable Solutions Bio-Pharma: China 2010-2020 A Look at The FUTURE: 4 th & 5 th Generation Global Strategies France Houdard Managing Director January 2010 Table of

More information

Dawn of a Post Venture Era: The New Face of Innovation & Translational Research BIO 2017 Annual Meeting June 2017

Dawn of a Post Venture Era: The New Face of Innovation & Translational Research BIO 2017 Annual Meeting June 2017 Dawn of a Post Venture Era: The New Face of Innovation & Translational Research BIO 2017 Annual Meeting June 2017 Mark G. Edwards Managing Director The New Face of Innovation & Translational Research A

More information

NPV Model and Analyzer

NPV Model and Analyzer July 2015 NPV Model and Analyzer User Guide to Methodology X STRICTLY CONFIDENTIAL PAGE 2 JULY 2015 Table of Contents TABLE OF CONTENTS... 2 OVERVIEW... 3 INTRODUCTION... 3 NPVS FROM EVALUATEPHARMA ALPHA...

More information

REFERENCE CODE GDHC1106CFR PUBLICATION DATE M AY 2013

REFERENCE CODE GDHC1106CFR PUBLICATION DATE M AY 2013 REFERENCE CODE GDHC1106CFR PUBLICATION DATE M AY 2013 PSORIASIS - Psoriasis - US Drug Forecast and Market Analysis to Executive Summary Sales for Psoriasis in the US 2012 We estimate the 2012 PsO drug

More information

Future Pharma - Challenges & Trends MES Process & Minds Conference Berlin, Germany, September 2015

Future Pharma - Challenges & Trends MES Process & Minds Conference Berlin, Germany, September 2015 Future Pharma - Challenges & Trends MES Process & Minds Conference Berlin, Germany, 28-29 September 2015 (PhD) Agenda Key challenges facing the Pharmaceutical Industry 1. Delivering shareholder/stakeholder

More information

Investor Presentation: Phase II Data for LCP Tacro. March 3, 2008

Investor Presentation: Phase II Data for LCP Tacro. March 3, 2008 Investor Presentation: Phase II Data for LCP Tacro March 3, 2008 FORWARD LOOKING STATEMENTS This presentation contains forward looking statements. The words believe, expect, anticipate, intend, will, may,

More information

Biotechnology Report. Turkey

Biotechnology Report. Turkey Biotechnology Report Turkey PREPARED BY AND IN 009 Cyprus Bulgaria Croatia Czech Estonia Hungary Latvia Lithuania Malta Poland Romania Slovak Slovenia Turkey Industry Republic Report STATUS OF THE TURKISH

More information

Pharma R&D and Patents support Health Care & Economy

Pharma R&D and Patents support Health Care & Economy Pharma R&D and Patents support Health Care & Economy Konstantinos Μ. Frouzis President of SFEE, V.P & Gen. Manager of Novartis Hellas April 28 th, 2014 Intellectual Property Patents: The vehicle for innovation

More information

National Foundation for Women Legislators Annual Meeting September 12, 2015 Tara Ryan Vice President, State Government Advocacy

National Foundation for Women Legislators Annual Meeting September 12, 2015 Tara Ryan Vice President, State Government Advocacy From Hope to Cures: The Value of Biopharmaceutical Innovation National Foundation for Women Legislators Annual Meeting September 12, 2015 Tara Ryan Vice President, State Government Advocacy HIV/AIDS: Then

More information

Amgen Supply Chain Segmentation The Journey to October 23, 2014

Amgen Supply Chain Segmentation The Journey to October 23, 2014 Amgen Supply Chain Segmentation The Journey to 2022 October 23, 2014 Introduction Rayne Waller VP Global Supply Chain at Amgen Responsible for: Corporate and Regional Supply Chain Functions Contract Manufacturing

More information

On Helix. 02 July Harren Jhoti President & CEO

On Helix. 02 July Harren Jhoti President & CEO On Helix 02 July 2014 Harren Jhoti President & CEO Astex Pharmaceuticals Global developer of small molecule drugs for unmet medical needs Expertise in oncology discovery & development World-class fragment-based

More information

Dealdoc. Marketing agreement for Recombinant Human Insulin, Glargine, Aspart and Lispro biosimilars (terminated) Pfizer Biocon.

Dealdoc. Marketing agreement for Recombinant Human Insulin, Glargine, Aspart and Lispro biosimilars (terminated) Pfizer Biocon. Dealdoc Marketing agreement for Recombinant Human Insulin, Glargine, Aspart and Lispro biosimilars (terminated) Pfizer Biocon Oct 18 2010 Marketing agreement for Recombinant Human Insulin, Glargine, Aspart

More information

United States, EU, Japan, China, India and Southeast Asia Telecom CRM Market Size, Status and Forecast 2021

United States, EU, Japan, China, India and Southeast Asia Telecom CRM Market Size, Status and Forecast 2021 United States, EU, Japan, China, India and Southeast Asia Telecom CRM Market Size, Status and Forecast 2021 #809814 $3300 90 pages In Stock Report Description Notes: Production, means the output of Telecom

More information

Global Life Sciences BPO Market to be Worth USD 596 Billion by 2019: Transparency Market Research

Global Life Sciences BPO Market to be Worth USD 596 Billion by 2019: Transparency Market Research Transparency Market Research Global Life Sciences BPO Market to be Worth USD 596 Billion by 2019: Transparency Market Research Buy Now Request Sample Published Date: April 2014 Single User License: US

More information

The UK Life Sciences Industry and the Public Markets, 2016/17. World class science, world class investment opportunities

The UK Life Sciences Industry and the Public Markets, 2016/17. World class science, world class investment opportunities The UK Life Sciences Industry and the Public Markets, 2016/17 World class science, world class investment opportunities Life sciences investment opportunity Biotechnology and related life science and healthcare

More information

Investor Presentation

Investor Presentation Siemens Ltd., 2 www.siemens.co.in Disclaimer This presentation has been prepared solely for use at the investor/analyst presentation. By attending the meeting where this presentation is made, or by reading

More information

Marketspace. Keywords: early-stage collaboration, licensing, lead optimisation, lead identification, target validation, drug discovery

Marketspace. Keywords: early-stage collaboration, licensing, lead optimisation, lead identification, target validation, drug discovery Mark J. Belsey spent his PhD looking at the role of cell signalling pathways underlying cell cycle progression in oncology. He is now working for the Competitive Intelligence healthcare team with Datamonitor,

More information

Investigating Clinical Trial Costs Comparative Analysis of Trial Cost Components in Key Geographies Table of Contents

Investigating Clinical Trial Costs Comparative Analysis of Trial Cost Components in Key Geographies Table of Contents Investigating Clinical Trial Costs Comparative Analysis of Trial Cost Components in Key Geographies Table of Contents Executive summary 14 Introduction and background to clinical trials 14 Financial considerations

More information

Pascal Quiry March 2013

Pascal Quiry March 2013 Please send any questions on this case study to the author via the mail box on the web site www.vernimmen.com Pascal Quiry March 2013 This document may not be used, reproduced or sold without the authorisation

More information

The Drug Importation Debate: An Economic Perspective

The Drug Importation Debate: An Economic Perspective The Drug Importation Debate: An Economic Perspective Patricia M. Danzon PhD The Wharton School University of Pennsylvania http://hc.wharton.upenn.edu/danzon/index.htm Effects of Legalizing Drug Importation

More information

The valuation of part-developed projects in the pharmaceutical sector

The valuation of part-developed projects in the pharmaceutical sector 050616ISP The valuation of part-developed projects in the pharmaceutical sector Masters of BioScience Enterprise Sangeeta Puran Fitwilliam College June 2005 Cambridge Healthcare & Biotech Ltd 18 Duxford

More information

a n d B i o s a fety C o n s i d e ra t i o n s

a n d B i o s a fety C o n s i d e ra t i o n s National University of Singapore Academy of GxP Excellence (NUSAGE) & PharmEng Technology Presents Good Laboratory Practices a n d B i o s a fety C o n s i d e ra t i o n s Part of the Pharmaceutical and

More information

Moberg Pharma AB. Interim report, January June 2016 CREATING A FOOTPRINT IN UNDERSERVED NICHES

Moberg Pharma AB. Interim report, January June 2016 CREATING A FOOTPRINT IN UNDERSERVED NICHES Moberg Pharma AB Interim report, January June 2016 CREATING A FOOTPRINT IN UNDERSERVED NICHES Conference call, August 9, 2016 at 3:00 p.m. (CET) Dial-in number: SE: +46 8 566 426 95, US: +1 646 502 51

More information

INVEST IN TOPADUR! HEALTH IS THE MOST IMPORTANT THING IN LIFE!

INVEST IN TOPADUR! HEALTH IS THE MOST IMPORTANT THING IN LIFE! INVEST IN TOPADUR! HEALTH IS THE MOST IMPORTANT THING IN LIFE! TOPADUR PHARMA AG a promising Swiss start-up investment Global Medical Need: Diabetes mellitus is one of the major health concerns worldwide.

More information

Global Forum on Competition

Global Forum on Competition Unclassified DAF/COMP/GF/WD(2014)51 DAF/COMP/GF/WD(2014)51 Unclassified Organisation de Coopération et de Développement Économiques Organisation for Economic Co-operation and Development 14-Feb-2014 English

More information

UBS Global Life Sciences Conference

UBS Global Life Sciences Conference September 21, 2010 UBS Global Life Sciences Conference Tecan Group AG Thomas Bachmann, CEO September 21, 2010 / p2 / UBS Global Life Sciences Conference Introducing Tecan Provider of instruments and workflow-solutions

More information

Contract Manufacturing of Biosimilars

Contract Manufacturing of Biosimilars Contract Manufacturing of Biosimilars Patti Seymour Senior Consultant BioProcess Technology Consultants, Inc. IBC Life Science s Biopharmaceutical Development and Production Huntington Beach, CA February

More information

Collaborative Development Financing

Collaborative Development Financing Collaborative Development Financing 14 by Warren Nachlis and Wendy Brasunas The Growth of the Biotechnology Industry Pharmaceutical drug development is a risky and very expensive process. According to

More information

File no./drug Name Name of firm/ Institute Recommendations. M/s. AstrazenecaPharma India Limited

File no./drug Name Name of firm/ Institute Recommendations. M/s. AstrazenecaPharma India Limited Recommendations: I agree the minutes of 51 st SEC-Oncology & Haematology meeting held on 21.03.2017 at CDSCO HQ New Delhi Agenda File /Drug Name Name of firm/ Institute Recommendations New Drugs Division

More information

Perspectives on BioPharma Innovation

Perspectives on BioPharma Innovation Perspectives on BioPharma Innovation David Thomas, CFA Senior Director, Industry Research & Policy Analysis BIO Presented to members of the National Conference of State Legislatures June 2016 BIOTECHNOLOGY

More information

Università Cattolica del Sacro Cuore

Università Cattolica del Sacro Cuore Università Cattolica del Sacro Cuore The role of Regulatory Affairs in drug development Francesco Mazza, Director of Legal, Fiscal & Compliance Affairs in Farmindustria Rome, May 12 2017 Who we are Who

More information

Portfolio management and product development in Actavis. 8 May 2007 Sigurdur O. Olafsson Deputy CEO

Portfolio management and product development in Actavis. 8 May 2007 Sigurdur O. Olafsson Deputy CEO Portfolio management and product development in Actavis 8 May 2007 Sigurdur O. Olafsson Deputy CEO Disclaimer Any statement contained in this presentation that refers to Actavis estimated or anticipated

More information

Biosimilar medicines rising to the cost challenge

Biosimilar medicines rising to the cost challenge Chapter 3 Biosimilar medicines rising to the cost challenge Addressing the rising cost of biological medicines has become a priority for governments and healthcare systems around the globe. Biosimilar

More information

Goldman Sachs Key Debates In Biosimilars Conference

Goldman Sachs Key Debates In Biosimilars Conference Goldman Sachs Key Debates In Biosimilars Conference Diem Nguyen Regional President North America, Global Established Pharmaceuticals April 2, 2015 1 2 Forward Looking Statements Our discussions during

More information

Valuing a Pharmaceutical Company This course is presented in London on: 27 February 2018, 13 November 2018

Valuing a Pharmaceutical Company This course is presented in London on: 27 February 2018, 13 November 2018 Valuing a Pharmaceutical Company This course is presented in London on: 27 February 2018, 13 November 2018 The Banking and Corporate Finance Training Specialist Course Objectives Participants will: Get

More information

UBS Global Life Sciences Conference

UBS Global Life Sciences Conference September 20, 2011 UBS Global Life Sciences Conference Tecan Group AG Dr. Rudolf Eugster, CFO September 20, 2011 / p2 / UBS GLSC Contents Introducing Tecan Strategic Growth Drivers Financials H1 2011 &

More information

Chin Koerner Executive Director US Regulatory and Development Policy

Chin Koerner Executive Director US Regulatory and Development Policy Chin Koerner Executive Director US Regulatory and Development Policy Novartis Pharmaceuticals Corporation 1700 Rockville Pike Suite 510 Rockville, MD 20852 Tel 301.468.5607 Fax 301.468.5614 Email: Chin.Koerner@novartis.com

More information

BIOTECHNOLOGY VALUATIONS FOR THE 21ST CENTURY

BIOTECHNOLOGY VALUATIONS FOR THE 21ST CENTURY P O L I C Y B R I E F BIOTECHNOLOGY VALUATIONS FOR THE 21ST CENTURY Number 27 B Y J E F F R E Y J. S T E W A R T BIOTECHNOLOGY VALUATIONS FOR THE 21ST CENTURY By Jeffrey J. Stewart jjs@alumni.princeton.edu

More information

A LEADING GLOBAL HEALTH CARE GROUP. Frankfurt stock exchange (DAX30): FRE US ADR program (OTC): FSNUY

A LEADING GLOBAL HEALTH CARE GROUP. Frankfurt stock exchange (DAX30): FRE US ADR program (OTC): FSNUY A LEADING GLOBAL HEALTH CARE GROUP Frankfurt stock exchange (DAX30): FRE US ADR program (OTC): FSNUY www.fresenius.com/investors SAFE HARBOR STATEMENT This presentation contains forward-looking statements

More information

European Commission s strategy for single market Using Bolar and the SPC Wavier to Stimulate Growth in the EU

European Commission s strategy for single market Using Bolar and the SPC Wavier to Stimulate Growth in the EU European Commission s strategy for single market Using Bolar and the SPC Wavier to Stimulate Growth in the EU Ravinder Chahil Director of Intellectual Property Polpharma Group SA 8 March 2016 Content Commission

More information

Opportunities in the Health Care Practice at Analysis Group

Opportunities in the Health Care Practice at Analysis Group Opportunities in the Health Care Practice at Analysis Group Johns Hopkins Blomberg School of Public Health October 3, 2016 You Will Learn Today: Who the Analysis Group is What our Health Care Practice

More information

Ophthalmology is our singular focus Akira Kurokawa President & CEO, Santen Pharmaceutical Co., Ltd.

Ophthalmology is our singular focus Akira Kurokawa President & CEO, Santen Pharmaceutical Co., Ltd. Ophthalmology is our singular focus Akira Kurokawa President & CEO, Santen Pharmaceutical Co., Ltd. J.P. Morgan Healthcare Conference January 8, 2018 Disclosure Notice 2 Information given in presentation

More information

Vince Anicetti EVP Quality and Compliance, Coherus Biosciences West Coast PDA 20 October 2016

Vince Anicetti EVP Quality and Compliance, Coherus Biosciences West Coast PDA 20 October 2016 Quality Management in a Virtual Environment Vince Anicetti EVP Quality and Compliance, Coherus Biosciences West Coast PDA 20 October 2016 Biosimilars - the second wave of biotech -an evolving regulatory

More information

2017 Clinical Trials Data Library

2017 Clinical Trials Data Library 2017 Clinical Trials Data Library Copyright 2017 CenterWatch. Investigator Databank Total Active Principal Investigators Worldwide Active Investigators Worldwide Global Distribution of Investigative Sites

More information

Global Pre-filled Syringes Market-Data, Analysis and Forecast to 2024

Global Pre-filled Syringes Market-Data, Analysis and Forecast to 2024 Global Pre-filled Syringes Market-Data, Analysis and Forecast to 2024 Pharmaceutical, healthcare, commercial and strategic developments in the Global Pre-Filled Syringes Market 2014-2024 www.gmrdata.com

More information

Global and China Hemodialysis Industry Report, May 2014

Global and China Hemodialysis Industry Report, May 2014 Global and China Hemodialysis Industry Report, 2013-2016 May 2014 STUDY GOAL AND OBJECTIVES This report provides the industry executives with strategically significant competitor information, analysis,

More information

White paper The Polish pharmaceutical market has undergone many changes as a result of the new Reimbursement Act

White paper The Polish pharmaceutical market has undergone many changes as a result of the new Reimbursement Act White paper The Polish pharmaceutical market has undergone many changes as a result of the new Reimbursement Act Published: July 2014 Author: Anantharaman Kavassery Viswanthan Anantharaman Kavassery Viswanathan

More information

Global Workforce Analytics: The Next Big Thing? Featuring: Linda E. Amuso Radford Dan Weber Radford

Global Workforce Analytics: The Next Big Thing? Featuring: Linda E. Amuso Radford Dan Weber Radford Global Workforce Analytics: The Next Big Thing? Featuring: Linda E. Amuso Radford Dan Weber Radford Session Agenda Creating a Foundation for Analytics People & Spend Analytics Performance & Spend Analytics

More information

SAMPLE. Mexico Orthopedic Prosthetics Market Outlook to Reference Code: GDMECC0156DB. Publication Date: February 2014

SAMPLE. Mexico Orthopedic Prosthetics Market Outlook to Reference Code: GDMECC0156DB. Publication Date: February 2014 Mexico Orthopedic Prosthetics Market Outlook to 2020 Reference Code: GDMECC0156DB Publication Date: February 2014 Page 1 1 Table of Contents 1 Table of Contents... 2 1.1 List of Tables... 3 1.2 List of

More information

WHEN, WHY AND HOW TO OUTSOURCE BIOMANUFACTURING: THE ROLE OF SINGLE USE TECHNOLOGIES

WHEN, WHY AND HOW TO OUTSOURCE BIOMANUFACTURING: THE ROLE OF SINGLE USE TECHNOLOGIES WHEN, WHY AND HOW TO OUTSOURCE BIOMANUFACTURING: THE ROLE OF SINGLE USE TECHNOLOGIES John Coyne Sr. Manager: Bioprocessing Research and Development Manufacturing Pfizer, Inc. 23 Years Industry Experience,

More information

INITIATOR PHARMA: Q3 REPORT 2017

INITIATOR PHARMA: Q3 REPORT 2017 INITIATOR PHARMA: Q3 REPORT 2017 Initiator Pharma A/S, a Danish Biotech Company developing a novel treatment of Erectile Dysfunction. Financial Highlights Initiator Pharma A/S is a Danish registered company,

More information

REFERENCE CODE GDHC266CFR PUBLICAT ION DATE DECEMBER 2014 RHEUMATOID ARTHRITIS JAPAN DRUG FORECAST AND MARKET ANALYSIS TO 2023

REFERENCE CODE GDHC266CFR PUBLICAT ION DATE DECEMBER 2014 RHEUMATOID ARTHRITIS JAPAN DRUG FORECAST AND MARKET ANALYSIS TO 2023 REFERENCE CODE GDHC266CFR PUBLICAT ION DATE DECEMBER 2014 RHEUMATOID ARTHRITIS JAPAN DRUG FORECAST AND MARKET ANALYSIS TO 2023 Executive Summary Sales for Rheumatoid Arthritis in Japan The Rheumatoid Arthritis

More information

From evidence to consequence The (new) reality for real world evidence

From evidence to consequence The (new) reality for real world evidence From evidence to consequence The (new) reality for real world evidence DLI MI 2017-2ND NORDIC CONFERENCE ON REAL WORLD DATA, COLLABORATION BETWEEN PHARMA INDUSTRY AND ACADEMIA 1 What we would like to discourse

More information

McKinsey Center for Government What's Driving the Recent Surge in New Drug Approvals?

McKinsey Center for Government What's Driving the Recent Surge in New Drug Approvals? McKinsey Center for Government What's Driving the Recent Surge in New Drug Approvals? Alexia Cesar, Philip Ma, Navjot Singh, Jeff Smith What's Driving the Recent Surge in New Drug Approvals? In 2012, the

More information

Insights into the Evolving Pricing & Market Access Environment

Insights into the Evolving Pricing & Market Access Environment Insights into the Evolving Pricing & Market Access Environment UBC Global Market Access Survey July 2012 JULY 2012 GLOBAL MARKET ACCESS SURVEY UBC s Global Market Access Survey: Setting the Stage For those

More information

A Leading Global Health Care Group

A Leading Global Health Care Group A Leading Global Health Care Group Roadshow Copenhagen October 6, 2015 For detailed financial information please see our annual/quarterly reports and/or conference call materials on www.fresenius.com/ir.

More information

The future of drug development. ISPOR Issues Panel May 19 th 2015

The future of drug development. ISPOR Issues Panel May 19 th 2015 The future of drug development ISPOR Issues Panel May 19 th 2015 Professor Adrian Towse Director of the Office of Health Economics Agenda Can we reduce drug development costs? Early access / adaptive pathways

More information

Life Sciences Practice

Life Sciences Practice Life Sciences Practice The healthcare landscape has recently experienced considerable changes, including highly visible public demands for safer and improved healthcare systems. At the core of this is

More information

Workshop on Access to and Uptake of Biosimilar Medicinal Products

Workshop on Access to and Uptake of Biosimilar Medicinal Products EUROPEAN COMMISSION Directorate-General for Internal Market, Industry, Entrepreneurship and SMEs Consumer, Environmental and Health Technologies Biotechnology and Food Supply Chain Workshop on Access to

More information

SEB Nordic Seminar 2018

SEB Nordic Seminar 2018 SEB Nordic Seminar 2018 Leveraging Our Compliance DNA Drives Diversification Our Core Leveraging Our Compliance DNA Life Sciences Public Finance Enterprise DKK 1,597m (58%) DKK 385m (14%) DKK 237m (9%)

More information

Quantitative Evaluation of the Impact of Novartis Knowledge Center Information Services in Drug Discovery and Development

Quantitative Evaluation of the Impact of Novartis Knowledge Center Information Services in Drug Discovery and Development Qualitative and Quantitative Methods in Libraries (QQML) 3: 357 366, 2012 Quantitative Evaluation of the Impact of Novartis Knowledge Center Information Services in Drug Discovery and Development Leifang

More information

Roadmap for Solar PV. Michael Waldron Renewable Energy Division International Energy Agency

Roadmap for Solar PV. Michael Waldron Renewable Energy Division International Energy Agency Roadmap for Solar PV Michael Waldron Renewable Energy Division International Energy Agency OECD/IEA 2014 IEA work on renewables IEA renewables website: http://www.iea.org/topics/renewables/ Renewable Policies

More information

CTA/NDA Regulatory Landscape in China. Jack Xie, PhD, DABT SOT 2016

CTA/NDA Regulatory Landscape in China. Jack Xie, PhD, DABT SOT 2016 CTA/NDA Regulatory Landscape in China Jack Xie, PhD, DABT SOT 2016 Disclaimer The content of the following presentation represents solely author s view and may not reflect any position of Roche or China

More information

The Challenge of Pricing Combination Therapies

The Challenge of Pricing Combination Therapies The Challenge of Pricing Combination Therapies By David Greber and Srikant Vaidyanathan The role of combination therapies in medicine continues to grow. For the treatment of HIV/AIDS, cancer, and hepatitis

More information

Global Contract Research Organization (CRO) Market: Size, Trends & Forecasts ( ) November 2017

Global Contract Research Organization (CRO) Market: Size, Trends & Forecasts ( ) November 2017 Global Contract Research Organization (CRO) Market: Size, Trends & Forecasts (2017-2021) November 2017 Global Contract Research Organization (CRO) Market : Coverage Executive Summary and Scope Introduction/Market

More information

France Pressure Relief Devices Market Outlook to 2020

France Pressure Relief Devices Market Outlook to 2020 France Pressure Relief Devices Market Outlook to 2020 Reference Code: GDMECC0869DB Publication Date: October 2014 Page 1 1 Table of Contents 1 Table of Contents... 2 1.1 List of Tables... 3 1.2 List of

More information

Indian CRAMS players to cram in growth: CARE Ratings

Indian CRAMS players to cram in growth: CARE Ratings January, 2015 Credit Perspective : Indian CRAMS Indian CRAMS players to cram in growth: CARE Ratings CARE Ratings expects Indian Contract Research and Manufacturing Services (CRAMS) players to register

More information

Idorsia Company Profile

Idorsia Company Profile Idorsia Headquartered in Switzerland - a biotech-hub of Europe - Idorsia is specialized in the discovery and development of small molecules, to transform the horizon of therapeutic options. Idorsia has

More information

7TH EPLS CONFERENCE PRAGUE, SEPTEMBER 23-24, 2014

7TH EPLS CONFERENCE PRAGUE, SEPTEMBER 23-24, 2014 7TH EPLS CONFERENCE PRAGUE, SEPTEMBER 23-24, 2014 PIERRE FABRE 2 2013 KEYS FIGURES PHARMACEUTICALS DERMO-COSMETICS TURNOVER TURNOVER: 910 M ; 45% TURNOVER: 1089 M ; 54% 2008 M 3 FOOTPRINT GLOBAL REACH

More information

Global Pest Control Services Market: Trends, Opportunities and Forecasts ( )

Global Pest Control Services Market: Trends, Opportunities and Forecasts ( ) Global Pest Control Services Market: Trends, Opportunities and Forecasts (2016-2021) By Segment Residential and Commercial By Region- N.America, L.America, APAC, Europe, Middle East & Africa By Country

More information